Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2019-eular.1646

SAT0109 SMOKING CESSATION IN PATIENTS WITH RA IS ASSOCIATED WITH REDUCED CVD EVENT RATES AND IMPROVED LIPID PROFILES AND PREDICTS LOWER RA DISEASE ACTIVITY

Ida Kristiane Roelsgaard¹, Eirik Ikdahl², Silvia Rollefstad², Grunde Wibetoe², Bente Appel Esbensen¹, George D. Kitas^{3,4}, Piet van Riel⁵, Sherine Gabriel⁶, Tore K. Kvien⁷, Karen Douglas⁸, Solveig Wallberg Jonsson⁹, Solbritt Rantapaa Dahlqvist⁹, George Karpouzas¹⁰, Patrick Dessein^{11,12}, Linda Tsang¹², Hani El-Gabalawy¹³, Carol Hitchon¹³, Virginia Dr. Pascual¹⁴, Irazu Contreras-Yáñez¹⁴, Petros Sfikakis¹⁵, Miguel A. González-Gay¹⁶, Cynthia S. Crowson⁶, Anne Grete Semb². ¹Rigshospitalet, Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research (COPE CARE), Glostrup, Denmark; ²Diakonhjemmet Hospital, Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Oslo, Norway; ³Dudley Group NHS Foundation Trust, West Midlands, United Kingdom; ⁴University of Birmingham, School of Sport, Exercise and Rehabilitation, Birmingham, United Kingdom; ⁵Radboud University Medical Center, Radboud Institute for Health Sciences, IQ healthcare, Nijmegen, Netherlands; ⁶Mayo Clinic, Department of Medicine, Division of Rheumatology, Rochester, MN, United States of America; ⁷Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway; ⁸Dudley Group NHS Foundation Trust, West Midlands, United Kingdom; ⁹Umeå University, Department of Public Health and Clinical Medicine, Rheumatology, Umeå, Sweden; ¹⁰Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, United States of America; ¹¹Vrije Universiteit Brussel, Brussel, Belgium; ¹²Universitair Ziekenhuis Brussel, Brussel, Belgium; ¹³University of Manitoba, Winnipeg, MB, Canada; ¹⁴Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México City, Mexico; ¹⁵National and Kapodistrian University of Athens, First Department of Propedeutic Internal Medicine, Athens, Greece; ¹⁶Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Universidad de Cantabria, Santander, Spain

Background: Smoking is a major risk factor for development of both cardiovascular disease (CVD) and rheumatoid arthritis (RA) and causes an attenuated response to antirheumatic treatment.

Objectives: The aim of this study was to compare disease activity and CVD risk factors across smoking status in RA patients. Further to evaluate the impact of smoking cessation on risk of future CVD events in these patients.

Methods: RA disease characteristics, CVD risk factors and relevant medication were recorded in patients from 10 countries (Norway, UK,

Netherlands, USA, Sweden, Greece, South Africa, Spain, Canada and Mexico). Information on CVD events were collected after a median follow-up of 3.54 years (inter-quartile range 2.51 – 6.06). Adjusted analysis of variance, logistic regression and COX proportional hazards analyses with time to event as response variable were applied to compare RA disease activity (measured by DAS28), CVD risk factors and CVD event rates across current, former and never smokers.

Results: Among the 3311 included RA patients (1012 former, 887 current and 1412 never smokers), 235 experienced a CVD event(s) during follow-up. At enrollment into the study current smokers were more likely to have moderate/high disease activity compared to former and never smokers ($p < 0.001$ for both) (Figure 1). There was a gradient of worsening CVD risk factor profiles (lipoproteins and blood pressure) from never smokers, via former smokers, to current smokers. Furthermore, after 3.54 years of follow up former and never smokers had significantly lower CVD event rates compared to current smokers (hazard ratio (95% confidence interval): 0.70 (0.51, 0.95), $p = 0.02$ and 0.48, (0.34, 0.69), $p < 0.001$, respectively) (figure 2). The CVD event rates for former and never smokers were comparable.

Conclusion: We show for the first time that smoking cessation in RA patients was associated with lower disease activity, improved lipid profiles and was a predictor of reduced rates of CVD events.

Figure 1. Disease activity across smoking status

Figure 2. Risk of future CVD event across smoking status in RA patients

COX proportional hazards regression model adjusted for age, sex, statin and antihypertensive use. HR: hazard ratio, 95% CI: 95% confidence interval.

Disclosure of Interests: Ida Kristiane Roelsgaard: None declared, Eirik Ikdahl: None declared, Silvia Rollefstad: None declared, Grunde Wibetoe: None declared, Bente Appel Esbensen Speakers bureau: For Pfizer, George D Kitas Speakers bureau: GDK has received honoraria for lectures, participation in advisory boards and/or hospitality by Roche, Abbvie, Pfizer, Novartis, UCB, BMS, GSK and received grant support from Lilly., Piet van Riel: None declared, Sherine Gabriel: None declared, Tore K. Kvien Grant/research support from: AbbVie, BMS, MSD, Pfizer, Roche and UCB., Consultant for: AbbVie, Biogen, BMS, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Hospira, Merck-Serono, MSD, Novartis, Oktal, Orion Pharma, Pfizer, Roche, Sandoz, Sanofi, Mylan and UCB, Speakers bureau: AbbVie, Biogen, BMS, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Hospira, Merck-Serono, MSD, Novartis, Oktal, Orion Pharma, Pfizer, Roche, Sandoz, Sanofi and UCB, Karen Douglas: None declared,

Solveig Wallberg Jonsson: None declared, Solbritt Rantapää Dahlqvist: None declared, George Karpouzas Grant/research support from: Pfizer, Consultant for: Sanofi-Genzyme-Regeneron, Janssen, Roche-Genentech, Pfizer, Speakers bureau: BMS, Sanofi-Genzyme-Regeneron, Janssen, Roche-Genentech, Patrick Dessein: None declared, Linda Tsang: None declared, Hani El-Gabalawy: None declared, Carol Hitchon: None declared, Virginia Dr. Pascual: None declared, Irazu Contreras-Yáñez: None declared, Petros Sfrikakis: None declared, Miguel A González-Gay Grant/research support from: Prof. MA Gonzalez-Gay received grants/research supports from Abbvie, MSD, Jansen and Roche., Speakers bureau: Consultation fees/participation in company sponsored speaker's bureau from Pfizer, Lilly, Sobi, Celgene, Novartis, Roche and Sanofi., Cynthia S. Crowson: None declared, Anne Grete Semb: None declared
DOI: 10.1136/annrheumdis-2019-eular.792

SAT0110 HIGH SERUM LONG-CHAIN OMEGA-3 FATTY ACIDS ARE ASSOCIATED WITH 6-MONTH LOWER DISEASE ACTIVITY IN EARLY RA: RESULTS FROM THE ESPOIR COHORT

Johanna Sigaux¹, Camille de Brauer Buscaill², Chantal Julia², Rene Marc Flipo³, Alain Cantagrel⁴, Bernard Bannwarth⁵, Francois Laporte⁶, Marie-Christophe Boissier¹, Luca Semerano¹. ¹INSERM UMR 1125, Université Paris 13, Bobigny, France; ²EREN UMR U1153 Inserm/U1125 Inra/Cnam/Univ Paris 13, Bobigny, France; ³Department of Rheumatology, Lille University Hospital, 59037, Lille, France; ⁴Centre de Rhumatologie, CHU de Toulouse, 31059, Toulouse, France; ⁵Service de rhumatologie, hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France; ⁶Département de Biochimie- Pharmacologie-Toxicologie CHU de Grenoble., Grenoble, France

Background: Dietary long-chain polyunsaturated fatty acids (PUFAs) of the n3 and n6 families are involved in immune homeostasis and can contribute to modulate inflammatory processes. Dietary intake of n3PUFA (by either supplementation or fish consumption) has been inversely associated with RA incidence in different populations. Some evidence suggests that, in subject at high risk of developing rheumatoid arthritis (RA), high erythrocyte membrane content in long-chain n3-PUFA is associated with lower ACPA prevalence and progression to RA. While long-chain n6PUFA are considered mainly proinflammatory, some, like gamma-linolenic acid (GLA), are endowed with anti-inflammatory activity, and the erythrocyte content in n6 linoleic acid was inversely associated with the development of RA in a nested-case control study. No study hitherto evaluated the longitudinal association between individual PUFA profile and disease activity in early RA.

Objectives: To characterize serum profiles of PUFA and to determine their association with baseline variables and with 6-month disease activity in a cohort of patients with early RA.

Methods: Serum PUFAs were quantified by gas chromatography-mass spectrometry (GC/MS) in 594 patients with early RA at the time of recruitment in the French Etude et Suivi des POLYarthrites Indifférenciées Récentes (ESPOIR) cohort. Principal component analysis on 19 serum fatty acids with 14 to 22 carbon atoms allowed to determine 3 orthogonal patterns of baseline serum PUFA. Pattern 1 included high proportions of short-chain fatty acids, pattern 2 was high in n3 long-chain PUFA (EPA et DHA), pattern 3 was rich in n6 long-chain fatty acids (among which, GLA had the highest concentration). Patients were stratified in tertiles according to how much the fitted into each pattern, with tertile 1 meaning lowest and tertile 3 highest fitting into the pattern. The association of PUFA patterns with baseline variables was tested in univariate analysis. The association with 6-month disease activity (with high disease activity defined as DAS28>5.1) was tested in multivariable analysis after adjustment on baseline CRP, corticosteroid and/or NSAIDs use, socioeconomic status, ACPA and RF positivity, traditional and biologic DMARDs treatment between 0 and 6 months after inclusion.

Results: In baseline univariate analysis, pattern 1 was associated with high BMI, active smoking and with non-Caucasian origin. Profile 2 was associated with higher socioeconomic status and inversely associated with DAS28 and CRP. Profile 3 was associated with ACPA positivity and higher baseline CRP. In multivariate analysis, fitting into pattern 2 and 3 was associated with lower odds of having active disease after 6 months (OR for tertile 3 vs. tertile 1: 0.49 (95% CI 0.25 to 0.97, p<0.05) for pattern 2 and 0.51 (0.28 to 0.95) for pattern 3, respectively).

Conclusion: In a cohort of early RA patients, we could identify a high serum long-chain n3PUFA profile associated with low disease activity between 0 and 6 months of follow-up in the cohort. This is consistent with a presumed immunomodulatory action of n3PUFA. Despite the baseline association with disease severity features, like ACPA positivity and

high CRP, a high serum long-chain n6PUFA profile is also associated with 6-month lower disease activity, possibly due to the presence of high concentrations of GLA in this profile.

Disclosure of Interests: Johanna Sigaux Speakers bureau: celgene, Camille de Brauer Buscaill: None declared, Chantal Julia: None declared, Rene Marc Flipo: None declared, Alain Cantagrel: None declared, Bernard Bannwarth: None declared, Francois Laporte: None declared, marie-Christophe Boissier Grant/research support from: Pfizer MSD, Speakers bureau: Pfizer Lilly Biogen, Luca Semerano Grant/research support from: pfizer, Speakers bureau: pfizer, roche, msd.

DOI: 10.1136/annrheumdis-2019-eular.5911

SAT0111 RED CELL DISTRIBUTION WIDTH IS A MARKER OF EARLY RESPONSE TO METHOTREXATE IN RHEUMATOID ARTHRITIS

Daniele Soddu^{1,2}, Mattia Bellan³, Erika Zecca¹, Alessandro Croce¹, Roberta Pedrazzoli¹, Daniele Sola^{1,2}, Mario Pirisi³, Pierpaolo Sainaghi³. ¹AOU "Maggiore della Carità" Hospital, Internal Medicine Division, Immunorheumatology Unit, Novara, Italy; ²Università del Piemonte Orientale, Department of Translational Medicine, Novara, Italy; ³Interdisciplinary Center of Autoimmune Diseases–IRCAD, Novara, Italy

Background: Red blood cell distribution width (RDW) has recently emerged as a possible surrogate biomarker of inflammation. Its potential role as prognostic biomarker has not been evaluated yet in Rheumatoid Arthritis (RA).

Objectives: The following study aims to evaluate the potential prognostic role of RDW in the prediction of early response to methotrexate (MTX).

Methods: We performed a retrospective analysis of clinical records of patients affected by RA, according to ACR/Eular classification Criteria. The baseline RDW was recorded and correlated with disease activity scores and inflammatory markers. The response to treatment was evaluated at the 3-months follow-up visit according to Eular response criteria.

Results: We selected 88 patients (58 females, 65.9%), with a median age of 62 [52-69] years. 61 patients were positive for Rheumatoid Factor (RF) and/or anticitrullinated antibodies – anti-CCP (69.3%). The median DAS28 for Erythrocyte sedimentation rate (DAS28ESR) at the diagnosis was 4.16 [3.33-5.00] while the median RDW was 14.0 [13.1-14.9]%. The baseline RDW was directly associated to CRP ($\rho = 0.250$; $p = 0.02$), but not with ESR ($p = 0.32$) or DAS28ESR ($p = 0.40$).

All the patients received methotrexate (MTX) at a median dose of 10 [10-15] mg/week, 79 (89.8%) also received prednisone (median dose 5 [5-10] mg/day) and 20 hydroxychloroquine in addition to MTX. A significant trend towards a larger RDW was reported from patients with a good Eular response at three months (13.5 [13.0-14.4]%) to those with a moderate response (14.0 [13.2-14.7]%) and finally to those with a poor response (14.6 [13.6-16.0]%; $p = 0.004$). At logistic regression, RDW ($p = 0.02$), but not CRP or ESR ($p = 0.70$ and $p = 0.37$ respectively), was a predictor of a good Eular response.

Moreover, in a further logistic regression model, baseline RDW ($p = 0.03$) and baseline DAS28ESR ($p = 0.0009$) were the only predictors of a good Eular response at three months, while age, gender, MTX and prednisone dosage and seropositivity did not fit the model.

After the treatment RDW significantly increases (14.7 [14.0-15.7]%) and the variation of RDW from baseline is inversely related to the variation of DAS28ESR ($\rho = -0.263$; $p = 0.02$). The increase of RDW is significantly higher in patients with a good Eular response, with a trend towards a smaller increase in case of moderate and poor response (0.95 [0.35-1.35]% vs. 0.65 [0.1-1.9]% vs. 0.2 [-0.62-0.77]%; $p = 0.015$).